地舒单抗治疗与临床诊断肩袖撕裂风险降低相关:多机构真实世界队列研究
这项多机构回顾性队列研究评估地舒单抗与临床诊断肩袖撕裂风险的关系。与单次给药和双膦酸盐相比,持续地舒单抗使用与较低的肩袖撕裂发生率相关,提示地舒单抗对腱骨界面无不良影响。
要点
- 持续地舒单抗使用者非创伤性肩袖撕裂风险低于单次给药者(0.7% vs 0.9%;HR,0.42;95%CI,0.37-0.48)。
- 地舒单抗使用者临床诊断肩袖撕裂风险低于双膦酸盐使用者(0.7% vs 0.9%;HR,0.80;95%CI,0.73-0.88)。
- 地舒单抗对腱骨界面无不良影响,可能与临床相关肩袖病变有保护性关联。
核心结论
- 地舒单抗治疗与临床诊断肩袖撕裂发生率降低相关,提示对腱骨界面无不良影响。
研究设计与样本
- 回顾性队列研究,使用TriNetX全球研究网络,纳入年龄≥50岁成人。
- 采用停药设计(持续地舒单抗使用者 vs 单次给药者)和活性对照设计(新地舒单抗使用者 vs 新双膦酸盐使用者)。
- 排除既往肩袖撕裂或Paget病患者,应用倾向性评分匹配和225天界标分析,Cox比例风险模型估计风险比。
- 停药队列每组61,952例,活性对照队列每组113,949例。
主要发现
- 停药分析中,持续地舒单抗使用与非创伤性肩袖撕裂风险降低相关(0.7% vs 0.9%;HR,0.42;95%CI,0.37-0.48)。
- 活性对照分析中,地舒单抗使用者临床诊断肩袖撕裂风险低于双膦酸盐使用者(0.7% vs 0.9%;HR,0.80;95%CI,0.73-0.88)。
- 临床诊断总体肩袖撕裂观察到相似趋势;手术结局在停药分析中降低,但在活性对照分析中无显著差异。
临床怎么用
- 对于≥50岁使用地舒单抗的患者,可关注其肩袖撕裂风险可能较低,但需结合个体情况评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: This large multi-institutional cohort study evaluated whether denosumab therapy is associated with rotator cuff tear risk. Denosumab use was associated with a lower incidence of clinically diagnosed rotator cuff tears compared with discontinuation and bisphosphonate therapy, suggesting no adverse association with tendon-to-bone integrity. PURPOSE: To evaluate whether denosumab therapy is associated with the risk of clinically diagnosed rotator cuff tears in adults aged ≥ 50 years. METHODS: A retrospective cohort study was conducted using the TriNetX global research network. Two analytic strategies were used: a discontinuation design comparing continued denosumab users with single-dose users and an active-comparator design comparing new denosumab users with new bisphosphonate users. Patients with prior rotator cuff tear or Paget disease were excluded. Propensity score matching and landmark analysis at 225 days were applied. Cox proportional hazards models estimated hazard ratios. RESULTS: After matching, 61,952 patients per group were included in the discontinuation cohort and 113,949 per group in the active-comparator cohort. In the discontinuation analysis, continued denosumab use was associated with a lower risk of nontraumatic RC tear compared with single-dose users (0.7% vs 0.9%; HR, 0.42; 95% CI, 0.37-0.48). In the active-comparator analysis, denosumab users also had a lower risk of clinically diagnosed RC tear than bisphosphonate users (0.7% vs 0.9%; HR, 0.80; 95% CI, 0.73-0.88). Similar trends were observed for clinically diagnosed overall RC tears. Surgical outcomes were reduced in the discontinuation analysis but were not significantly different in the active-comparator analysis. CONCLUSIONS: Denosumab therapy was associated with a reduced incidence of clinically diagnosed rotator cuff tears compared with both discontinuation and bisphosphonate therapy. These findings suggest that denosumab does not adversely affect the tendon-to-bone interface and may have a protective association with clinically relevant rotator cuff pathology.
引用
- Yen HK, Chen IH, Wang HY, et al. Denosumab therapy is associated with a reduced risk of clinically diagnosed rotator cuff tears: a multi-institutional real-world cohort study. Osteoporos Int. 2026. PMID: 42406060. doi:10.1007/s00198-026-08133-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。